Bendamustine HCL
Total Payments
$77,620
Transactions
18
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $77,620 | 18 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $77,620 | 18 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| EAGL11.5860 Bendamustine HCL BDM | Eagle Pharmaceuticals, Inc. | $64,808 | 0 |
| EAGL11.5860 Bendamustine HCL (BDM) | Eagle Pharmaceuticals, Inc. | $12,812 | 0 |
Top Doctors Receiving Payments for Bendamustine HCL
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Wichita, KS | $77,620 | 18 |
Ad
Manufacturing Companies
- Eagle Pharmaceuticals, Inc. $77,620
Product Information
- Type Drug
- Total Payments $77,620
- Total Doctors 0
- Transactions 18
About Bendamustine HCL
Bendamustine HCL is a drug associated with $77,620 in payments to 0 healthcare providers, recorded across 18 transactions in the CMS Open Payments database. The primary manufacturer is Eagle Pharmaceuticals, Inc..
Payment data is available from 2017 to 2017. In 2017, $77,620 was paid across 18 transactions to 0 doctors.
The most common payment nature for Bendamustine HCL is "Unspecified" ($77,620, 100.0% of total).
Bendamustine HCL is associated with 2 research studies, including "EAGL11.5860 Bendamustine HCL BDM" ($64,808).